Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Xingqi Eye Medicine: SQ-129 Vitreous Sustained-Release Injection for Diabetic Macular Edema Phase I/II Clinical Trial First Subject Enrolled
Xingqi Eye Medicine announces that the first subject has been enrolled in the company’s research and development project, SQ-129 Vitreous Sustained-Release Injection, marking the official start of Phase I/II clinical trials for the “Assessment of the Safety, Pharmacokinetic Characteristics, and Preliminary Efficacy of SQ-129 Vitreous Sustained-Release Injection in the Treatment of Diabetic Macular Edema.”